Asacol

See also: Generic Asacol HD

Asacol is a brand name of mesalamine, approved by the FDA in the following formulation(s):

ASACOL (mesalamine - tablet, delayed release; oral)

• 
  Manufacturer: WARNER CHILCOTT LLC
  
  Approval date: January 31, 1992
  
  Strength(s): 400MG ^[RLD]

Has a generic version of Asacol been approved?

No. There is currently no therapeutically equivalent version of Asacol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Asacol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Orally administrable pharmaceutical compositions
  Patent 5,541,170
  Issued: July 30, 1996
  Inventor(s): Rhodes; John & Evans; Brian K.
  Assignee(s): Tillotts Pharma AG
  A solid dosage form, such as a capsule or tablet, containing a pharmacologically active agent is coated with an anionic polymer, which is insoluble in gastric juice and in intestinal juice below pH7 but soluble in colonic intestinal juice, in a sufficient amount that the oral dosage form remains intact until it reaches the colon. The preferred anionic polymer is a partly methyl esterified methacrylic acid polymer in which the ratio of free carboxylic groups to ester groups is about 1:2. The invention has particular application to dosage forms of prednisolone and salts thereof, indomethacin, ibuprofen, and, especially, 5-amino-salicylic acid.
  
  Patent expiration dates:
  
  
  • July 30, 2013
    
    ✓ 
    Patent use: TREATMENT OF ULCERATIVE COLITIS
  
  



• 
  Orally administrable pharmaceutical composition
  Patent 5,541,171
  Issued: July 30, 1996
  Inventor(s): Rhodes; John & Evans; Brian K.
  Assignee(s): Tillotts Pharma AG
  A solid dosage form, such as a capsule or tablet, containing a pharmacologically active agent is coated with an anionic polymer, which is insoluble in gastric juice and in intestinal juice below pH7 but soluble in colonic intestinal juice, in a sufficient amount that the oral dosage form remains intact until it reaches the colon. The preferred anionic polymer is a partly methyl esterified methacrylic acid polymer in which the ratio of free carboxylic groups to ester groups is about 1:2. The invention has particular application to dosage forms of prednisolone and salts thereof, indomethacin, ibuprofen, and, especially, 5-amino-salicylic acid.
  
  Patent expiration dates:
  
  
  • July 30, 2013
    
    ✓ 
    Patent use: TREATMENT OF ULCERATIVE COLITIS
  
  

See also...

• Asacol Consumer Information (Drugs.com)
• Asacol Delayed-Release Tablets Consumer Information (Wolters Kluwer)
• Asacol Consumer Information (Cerner Multum)
• Asacol Advanced Consumer Information (Micromedex)
• Asacol 800 Advanced Consumer Information (Micromedex)
• Mesalamine Controlled-Release Capsules Consumer Information (Wolters Kluwer)
• Mesalamine Delayed-Release Tablets Consumer Information (Wolters Kluwer)
• Mesalamine Enema Consumer Information (Wolters Kluwer)
• Mesalamine Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Mesalamine Suppositories Consumer Information (Wolters Kluwer)
• Mesalamine Consumer Information (Cerner Multum)
• Mesalamine rectal Consumer Information (Cerner Multum)
• Mesalamine Advanced Consumer Information (Micromedex)
• Mesalamine Rectal Advanced Consumer Information (Micromedex)
• SfRowasa Advanced Consumer Information (Micromedex)
• Mesalamine AHFS DI Monographs (ASHP)